Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

In 2030, Evaluate projects Lilly’s diabetes treatment Mounjaro will be the world’s top-selling drug, generating $36 billion, while the company’s obesity medicine Zepbound will be the third ...

Eli Lilly and Co. hosted its first “Ask Me Anything” session on the popular online forum Reddit on Monday, featuring a question-and-answer session with a Lilly executive about insurance ...